Matthew J. Frigault, M.d.

This early-stage study tested the safety of a personalized cell therapy called tisagenlecleucel in patients with primary central nervous system lymphoma, a rare and aggressive cancer of the brain. The therapy involves collecting a patient's own immune cells, modifying them in a l…